Myriad Genetics, Inc.
MYGNHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Myriad Genetics, Inc. focuses on Diagnostics & Research services and products. Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. Valued at $404.2M, MYGN is a small-cap name in its sector. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Market Cap
$404.2M
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
26.75
EPS (TTM)
$-4.31
EPS (Fwd)
$0.16
ROE
-23.5%
ROA
-7.6%
Cash
$150.7M
Total Debt
$0
Free CF
-$46.1M
52W Change
-12.3%
Annual Financials
Cash vs Debt
Myriad Genetics, Inc. reports $150.7M in cash and $0 in total debt. Free cash flow is running at -$46.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -23.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $678.4M (2022) to $824.5M (2025), reflecting a 22% increase over the period.
With a beta above 1.5, MYGN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MYGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.